

[CONTACT US](#) [LOGIN!](#)[I2V SCHEDULE](#)[ARCHIVE](#)[RESOURCES](#)[ABOUT](#)[ADVANCED](#)**I2V**

**Commercialization
in the Life Sciences**
[Kick Off Talk](#)
[Speakers](#)
[Agenda](#)
[Directions](#)
[Registration](#)

BONUS! PRE-WORKSHOP KICK OFF TALK:**Wednesday, March 11, 4:30 pm, OHSU Auditorium****"Connecting the Dots: How to Convert University Bioscience Research into a Successful Venture Outside Academia"***Speaker: M. Patricia Beckmann, PhD. Executive Director of the Oregon Translational Research and Drug Development Institute (OTRADI)***Topics covered include:**

Licensing to create a new company
Collaborating/licensing with existing corporations
Applying for government & foundation grants

The kick-off talk is intended as a "taster" of the above topics, which will be covered in-depth at the April 10 workshop.

COST: FREE (Registration is required. Click [HERE](#) to register.)

ABOUT THE SPEAKER:

Prominent researcher M. Patricia Beckmann, Ph.D. with more than 25 years of experience leading biotechnology projects and companies was recently named the Executive Director of the Oregon Translational Research and Drug Development Institute (OTRADI), the state's effort to commercialize therapeutics to combat infectious and other diseases via a collaboration between Oregon universities and industry.

M. Patricia Beckmann, Ph.D., was most recently a Kauffman Fellow at the Accelerator Corporation in Seattle and a Venture Partner with Northwest Technology Ventures fund in Portland. Beckmann served as the Chief Scientific Officer for Homestead Clinical Corporation, an Accelerator-backed start-up focused on the development of diagnostic biomarkers for oncology and other disease indications. Before that, she was a biotechnology investment specialist for Vulcan Capital, the investment platform for Microsoft Co-Founder Paul Allen.

Dr. Beckmann spent the majority of her career at Immunex Corporation (now Amgen) in research, administration and law. She is a co-inventor of Amgen's blockbuster rheumatoid arthritis drug Enbrel, as well as several other drugs in clinical trials. She was awarded National Inventor of the Year in 2001 for her work discovering TNF receptor molecules which led to the development of Enbrel.

Beckmann holds a Ph.D. in Biochemistry and Pharmacology. She pursued postdoctoral studies as a Fulbright Scholar at the Ludwig Institute in Uppsala, Sweden and at the National Cancer Institute in Bethesda, MD.



National Collegiate Inventors and Innovators Alliance
100 Venture Way Hadley MA 01035
T: 1.413.587.2172 // F. 1.413.587.2175 // W. www.nciia.org

©2007. NCIIA. All rights reserved.